5 Best-Performing Stocks Of The Top ETF Of January
Zacks Investment Research | Jan 30, 2018 09:46PM ET
The biotech sector took the credit in the first month of 2018 as Loncar Cancer Immunotherapy ETF M&A Waves Pushing Biotech ETFs Higher ). Let’s take a closer look at the fundamentals of CNCR. CNCR in Focus This product tracks the Loncar Cancer Immunotherapy Index and provides exposure to the basket of companies that develop therapies to treat cancer by harnessing the body’s own immune system. It holds 31 stocks in its basket with none holding more than 6.9% share. The ETF has amassed $47.4 million in its asset base and trades in a lower average daily volume of around 21,000 shares. The expense ratio comes in at 0.79%. Though most of the stocks in the fund’s portfolio delivered strong returns, a few even doubled. Below we have highlighted the five best-performing stocks in the ETF with their respective positions in the fund’s basket (see: Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.